Caribou Biosciences (CRBU) Operating Margin (2020 - 2026)
Caribou Biosciences (CRBU) reported Operating Margin of 1096.37% for Q1 2026, up 72739.0% year-over-year from N/an in Q1 2025, and down 51.86% on a QoQ basis from 721.97% in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Operating Margin data on file, last reported at 1096.37% in Q1 2026.
- Quarterly Operating Margin rose 72739.0% year-over-year to 1096.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1175.68% (up 47311.0% YoY) and the FY2025 annual result came in at 1329.37%, up 33779.0% from the prior year.
- Operating Margin slipped to 1096.37% in Q1 2026 per CRBU's latest filing, from 721.97% in the prior quarter.
- Across five years, Operating Margin topped out at 61.84% in Q3 2023 and bottomed at 1893.87% in Q1 2024.
- The 5-year median for Operating Margin is 1052.33% (2023), against an average of 1155.58%.
- The widest annual swing landed in 2024, when Operating Margin sank 182739 bps; it then soared 114972 bps in 2025.
- Tracing CRBU's Operating Margin over 5 years: stood at 828.22% in 2022, then decreased by 27 bps to 1052.33% in 2023, then sank by 78 bps to 1871.69% in 2024, then soared by 61 bps to 721.97% in 2025, then plunged by 52 bps to 1096.37% in 2026.
- Per Business Quant, the three latest CRBU Operating Margin figures stand at 1096.37% (Q1 2026), 721.97% (Q4 2025), and 1337.58% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -1,096.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,096.37% |
| Dec 31, 2025 | -721.97% |
| Sep 30, 2025 | -1,337.58% |
| Jun 30, 2025 | -1,783.95% |
| Mar 31, 2025 | -1,823.76% |
| Dec 31, 2024 | -1,871.69% |
| Sep 30, 2024 | -1,889.23% |
| Jun 30, 2024 | -1,255.80% |
| Mar 31, 2024 | -1,893.87% |
| Dec 31, 2023 | -1,052.33% |
| Sep 30, 2023 | -61.84% |
| Jun 30, 2023 | -875.31% |
| Mar 31, 2023 | -888.52% |
| Dec 31, 2022 | -828.22% |
| Sep 30, 2022 | -803.42% |
| Jun 30, 2022 | -678.22% |
| Mar 31, 2022 | -782.77% |
| Dec 31, 2021 | -797.38% |
| Sep 30, 2021 | -468.09% |
| Jun 30, 2021 | -1,081.57% |
| Mar 31, 2021 | -830.71% |
| Dec 31, 2020 | -1,545.83% |
| Sep 30, 2020 | -686.89% |
| Jun 30, 2020 | -26.60% |
| Mar 31, 2020 | -613.11% |